Actavis launches generic Keppra XR in US
This article was originally published in Scrip
The fourth largest generics company worldwide, Actavis has launched its Levetiracetam Extended-Release Tablets, a generic equivalent of UCB's Keppra XR, in the US following FDA approval on 15 September. The company began shipping the product immediately following approval.
Keppra XR, which launched in the US in 2008, is an anti-epileptic drug to treat patients with partial-onset seizures. According to IMS Health, it had US sales of approximately $161 million for the year ending 30 June 2011.